Drug Trial Radar · NCT06714825
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Nov 28, 2024
Primary completion
Dec 2, 2025
Study completion Dec 2, 2025
Sponsor
- Lead sponsor
- 35Pharma Inc., a GSK companyIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects
Conditions
- Overweight and Obesity
Interventions
HS235Biological
Up to 4 Single and 3 Multiple Ascending Doses
PlaceboDrug
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Number of Adverse Events (AEs)Time frame: up to 106 days for Single dose and 147 days for multiple doses
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos Clinical Research Unit
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.